COMPANY ANNOUNCEMENT
UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.
Read Announcement View Product PhotosSummary
- Company Announcement Date:
- FDA Publish Date:
- Product Type:
- Drugs
Generic Drugs - Reason for Announcement:
-
Recall Reason DescriptionLack of Sterility
- Company Name:
- Torrent Pharmaceuticals Limited
- Brand Name:
-
Brand Name(s)Torrent Pharmaceuticals Limited
- Product Description:
-
Product DescriptionLosartan potassium tablets, USP; Losartan potassium and Hydrochlorothiazide tablets, USP
Company Announcement
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.
The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per international Agency for Research on Cancer (IARC) classification. Torrent is only recalling lots of losartan containing products that contain Nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.
To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.
Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Patients who are on Losartan should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.
Patients who are on losartan potassium and hydrocholothiazide tablets, USP should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
The products subject to recall are listed below and packaged in bottles. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.
| NDC | Manufacturer | Product Description | Lot/Batch | Expiration Date |
|---|---|---|---|---|
| 13668- 115-30 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 100mg,30count bottles | BO31C016 | 04/2019 |
| 13668- 115-90 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 100mg,90count bottles | BO31C016 | 04/2019 |
| 13668- 115-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 100mg,1000-count bottles |
4DK3C005 | 04/2019 |
| 13668- 115-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 100mg,1000-count bottles |
4DK3C004 | 04/2019 |
| 13668- 115-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 100mg,1000-count bottles |
4DU3C040 | 10/2019 |
| 13668- 115-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 100mg,1000-count bottles |
4DU3E049 | 05/2021 |
| 13668- 115-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 100mg,1000-count bottles |
4DU3E050 | 05/2021 |
| 13668- 409-30 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 50mg,30count bottles | 4L67C035 | 10/2019 |
| 13668- 409-90
|
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 50mg,90count bottles | 4L67C035 | 10/2019 |
| 13668- 409-90 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 50mg,90count bottles | 4L67C036 | 10/2019 |
| 13668- 409-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 50mg,1000-count bottles |
4O50C005 | 11/2019 |
| 13668- 113-90 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM TAB, USP 25mg,90count bottles | 4O49C013 | 09/2019 |
| 13668- 116-90 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 50mg/12.5 mg, 90 count bottles. |
BP02C008 | 03/2019 |
| 13668- 116-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 50mg/12.5 mg, 1000 count bottles. |
BEF7D006 | 03/2020 |
| 13668- 117-90 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 90 count bottles. |
BX35C020 | 05/2019 |
| 13668- 117-90 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 90 count bottles. |
BX35C049 | 08/2019 |
| 13668- 117-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 1000 count bottles. |
BX35C022 | 05/2019 |
| 13668- 117-10 |
Torrent Pharmaceuticals LTD |
LOSARTAN POTASSIUM and HYDROCHOLOROTHIAZIDE TABLETS, USP 100 mg/12.5 mg, 1000 count bottles. |
BX35C023 | 05/2019 |
Losartan potassium tablets, USP were distributed nationwide to Torrent’s wholesale distributor, repackager and retail customers. Torrent Pharmaceuticals Limited is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Torrent is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.
Consumers with medical questions regarding this recall or to report an adverse event can contact Torrent Pharmaceuticals Limited at:
- 1-800-912-9561 (live calls received 8:00 am – 5:00 pm Eastern Time, voicemail available 24 hours/day, 7 days/week).
Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Any general questions regarding the return of this product should be directed to Qualanex at 1-888-280-2040 (live calls received 8 am - 9:00 pm Eastern Time).
Adverse reactions or quality problems associated with the use of this product may be reported to FDA's MedWatch Adverse Event Reporting program either by phone, on line, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Link to Original Recall
Link to Expanded Recall
